JP2019531346A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531346A5
JP2019531346A5 JP2019536463A JP2019536463A JP2019531346A5 JP 2019531346 A5 JP2019531346 A5 JP 2019531346A5 JP 2019536463 A JP2019536463 A JP 2019536463A JP 2019536463 A JP2019536463 A JP 2019536463A JP 2019531346 A5 JP2019531346 A5 JP 2019531346A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
group
substituted
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019536463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531346A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/051410 external-priority patent/WO2018053036A1/en
Publication of JP2019531346A publication Critical patent/JP2019531346A/ja
Publication of JP2019531346A5 publication Critical patent/JP2019531346A5/ja
Priority to JP2022148311A priority Critical patent/JP7656574B2/ja
Pending legal-status Critical Current

Links

JP2019536463A 2016-09-16 2017-09-13 甲状腺関連副作用を低下させる方法 Pending JP2019531346A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022148311A JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662396025P 2016-09-16 2016-09-16
US201662396015P 2016-09-16 2016-09-16
US62/396,015 2016-09-16
US62/396,025 2016-09-16
PCT/US2017/051410 WO2018053036A1 (en) 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022148311A Division JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Publications (2)

Publication Number Publication Date
JP2019531346A JP2019531346A (ja) 2019-10-31
JP2019531346A5 true JP2019531346A5 (enExample) 2020-10-22

Family

ID=61619247

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019536463A Pending JP2019531346A (ja) 2016-09-16 2017-09-13 甲状腺関連副作用を低下させる方法
JP2022148311A Active JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022148311A Active JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Country Status (9)

Country Link
US (1) US20190255080A1 (enExample)
EP (1) EP3512523A4 (enExample)
JP (2) JP2019531346A (enExample)
KR (2) KR20240074912A (enExample)
CN (1) CN109922812A (enExample)
AU (1) AU2017327383B2 (enExample)
CA (1) CA3037146A1 (enExample)
MX (2) MX2019003032A (enExample)
WO (1) WO2018053036A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
AU2017363206A1 (en) 2016-11-21 2019-06-13 Viking Therapeutics, Inc. Method of treating glycogen storage disease
CA3064940A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
AU2019238090B2 (en) 2018-03-22 2024-08-01 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
TWI875757B (zh) * 2019-05-08 2025-03-11 瑞士商諾華公司 T1dm和胰島炎治療中使用之抗cd40抗體
RU2728261C2 (ru) * 2019-05-22 2020-07-28 Ирина Алексеевна Курникова Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом
CN112457346B (zh) * 2019-08-19 2022-09-06 和博医药有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
AU2020334943A1 (en) * 2019-08-19 2022-03-10 Hepagene Therapeutics (HK) Limited Heterocyclic THR-β receptor agonist compound and preparation method and use therefor
JP7670687B2 (ja) * 2020-02-24 2025-04-30 へパジーン セラピューティクス (エイチケイ) リミテッド 複素環式THR-β受容体アゴニスト化合物ならびにその調製方法および使用
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
MXPA04012497A (es) * 2002-07-04 2005-07-14 Zealand Pharma As Glp-1 y metodos para tratar la diabetes.
RU2422450C2 (ru) * 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
CA2606499C (en) * 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2009089093A1 (en) * 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
WO2010074992A2 (en) * 2008-12-22 2010-07-01 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
JP6957601B2 (ja) * 2016-04-22 2021-11-02 メタベイシス・セラピューティクス・インコーポレイテッド 甲状腺ホルモン受容体アゴニスト及びその使用
AU2017363206A1 (en) * 2016-11-21 2019-06-13 Viking Therapeutics, Inc. Method of treating glycogen storage disease

Similar Documents

Publication Publication Date Title
JP2019531346A5 (enExample)
RU2020123241A (ru) Полициклические соединения в качестве аллостерических ингибиторов shp2
JP2016509047A5 (enExample)
JP2020505376A5 (enExample)
JP2020506178A5 (enExample)
JP2020515610A5 (enExample)
JP2020536881A5 (enExample)
JP2016505586A5 (enExample)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
JP2015532295A5 (enExample)
JP2019094345A5 (enExample)
JP2019512505A5 (enExample)
JP2017505314A5 (enExample)
JP2009526761A5 (enExample)
JP2007505933A5 (enExample)
JP2017526726A5 (enExample)
JP2020500866A5 (enExample)
JP2013512903A5 (enExample)
JP2017518959A5 (enExample)
JP2013542996A5 (enExample)
JP2016509583A5 (enExample)
JP2019518059A5 (enExample)
JP2019510787A5 (enExample)
RU2019116590A (ru) Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
JP2011519360A5 (enExample)